A substantial number of children with non-
The following conventions were used in assigning the deaths to these broad categories. Bronchopneumonia was often given as the cause of death in children who had gradually deteriorated with recurrent tumour; these deaths were all coded as tumour deaths rather than infection. If a child died from infection while receiving chemotherapy or within six months of stopping treatment the death was coded as treatment related. The death of one patient who had had a splenectomy and subsequently died of pneumococcal meningitis while in remission was also coded as treatment related. When death occurred from any cause and there was insufficient evidence to determine whether the patient had active disease at the time, then the death was coded as insufficient information. A second doctor reviewed all cases where the cause of death was coded as not due to the original tumour or where there was uncertainty about the cause of death.
Actuarial survival analysis was performed to determine the risks of dying from a particular cause of death in relation to type of treatment centre and whether the child had been included in a clinical trial. Children who did not receive any form of treatment or have a biopsy sample taken were excluded from the analyses of the mortality rates. In calculating rates for particular subcategories of cause of death, patients dying of causes other than that in question were censored at the time of death.
Results Table 1 shows the causes of death as assigned by us using all available sources of information.
There were three deaths for which the information available was insufficient to determine the cause of death. The numbers of deaths due to specific causes have been expressed as percentages of the remaining 476 deaths. Using all available sources we found that 377 (79%) died from non-Hodgkin's lymphoma and 99 (21%) died from other causes. Ten (2%) children died from second primary tumours; these consisted of six with acute myeloid leukaemia, two with with the change in coding practice, it remained low. Table 2 gives an analysis of the 86 deaths considered to be due to treatment related factors. The There were 19 deaths among children who had previously received a bone marrow transplant. Of these, 11 died from relapsed nonHodgkin's lymphoma. For the remaining eight children the causes of death were as follows: three graft versus host disease, three infections, one second primary tumour, and one cardiomyopathy. Table 4 gives the number of deaths due to non-Hodgkin's lymphoma and other causes for four different time periods of diagnosis. The total number of deaths and the number of deaths from non-Hodgkin's lymphoma decreased over the study period, but the number of deaths from causes other than non-Hodgkin's lymphoma has remained nearly constant. Thus as a proportion of the total deaths, these increased from 15% (26/173) for the years of diagnosis 1974-6, to 32% (20/62) for 1983-5.
The numbers in each category of deaths from causes other than non-Hodgkin's lymphoma are small but the data suggest that although the deaths from infection decreased with time, the treatment related deaths other than those from infection remained static within the period of follow up for the study. Total deaths not due to non-Hodgkin's lymphoma 26 (11) 32 (13) 21 (10) 20 (10) 99 ( 'Accident and other medical cause unrelated to tumour or its treatment.
latent interval for secondary leukaemias is four to six years and it therefore appears unlikely that many more of these will occur in this cohort. The 608 children who were diagnosed from 1977 (when the UKCCSG was formed) onwards and who received radiotherapy or chemotherapy for non-Hodgkin's lymphoma were classified according to whether they were treated at a paediatric oncology centre under a consultant who was a member of the UKCCSG and whether they were treated in the UKCCSG nonHodgkin's lymphoma trials (including the T cell trial and patients registered with the UKCCSG as receiving the modified first study protocol). The five year survival rate for the 484 UKCCSG patients was 61% compared with 41% for the 124 patients treated elsewhere. The five year survival for the 241 trial patients was 63%, whereas for the 367 non-trial children it was 54%. The actuarial risks of treatment related deaths were not significantly different between UKCCSG and non-UKCCSG patients (X2=0-39 on one degree of freedom) nor between trial and non-trial patients (X2=0-34 on one degree of freedom).
Discussion
This study has confirmed that the official statistics available on cause of death as determined from death certificates are inadequate for detecting treatment related deaths, even after the modification to coding of treatment related deaths introduced with the ninth revision of the International Classification of Diseases. Therefore if mortality is to be used as an outcome measure to detect severe treatment related effects, it is essential that all available sources of information are used to determine the precise cause of death.
During the period 1974-85 treatment for non-Hodgkin's lymphoma became increasingly intensive, producing a marked improvement in survival. The percentage of patients dying from causes other than non-Hodgkin's lymphoma did not increase during the study period, but as a result of the dramatic decrease in the percentage ofpatients dying from non-Hodgkin's lymphoma the proportion of the total number of deaths accounted for by causes other than nonHodgkin's lymphoma had doubled from 15% to 32%.
Treatment related mortality from infection nearly halved during the study period, presumably as a result of the improvements in general supportive management and increased availability of therapeutic and prophylactic antibiotics and antiviral agents.
It is of concern that the non-infective, treatment related mortality remained constant, but also reassuring that it has not increased. The largest subcategory within this group was the metabolic disorder deaths. These 1977-84.20 The risk of dying from a treatment related cause, however, did not vary significantly with the type of treatment centre or entry into trials. Despite apparently inadequate treatment outside paediatric oncology centres, the risk of death from a treatment related cause was just as high as for patients treated more effectively and presumably more aggressively in UKCCSG centres.
In conclusion, a substantial number of children diagnosed with non-Hodgkin's lymphoma during the period 1974-85 died from treatment related effects and as survival improves these deaths are becoming a larger proportion of the overall number of deaths. The number of deaths from infection is probably decreasing. Therefore further reductions in treatment related mortality are likely to depend on the prevention of deaths from metabolic and renal disorders, especially in children with intra-abdominal primary tumours, and in preventing deaths from complications of anaesthesia. As more is learnt about the aetiology of second primary tumours it may become possible to prevent some of them without compromising the present high survival rates for non-Hodgkin's lymphoma. Further improvements in survival for childhood non-Hodgkin's lymphoma will depend on maintaining the fine balance between the therapeutic value of intensive treatment and its potential harmful effects.
